Cargando…
YCharOS open antibody characterisation data: Lessons learned and progress made
YCharOS is a collaborative initiative aimed at characterising antibodies against the entire human proteome. As of August 2023, they have presented comprehensive knockout characterisation data for 812 antibodies and 78 proteins using techniques such as Western blot, immunoprecipitation, and immunoflu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579855/ https://www.ncbi.nlm.nih.gov/pubmed/37854875 http://dx.doi.org/10.12688/f1000research.141719.1 |
_version_ | 1785121819072659456 |
---|---|
author | Biddle, Michael S. Virk, Harvinder S. |
author_facet | Biddle, Michael S. Virk, Harvinder S. |
author_sort | Biddle, Michael S. |
collection | PubMed |
description | YCharOS is a collaborative initiative aimed at characterising antibodies against the entire human proteome. As of August 2023, they have presented comprehensive knockout characterisation data for 812 antibodies and 78 proteins using techniques such as Western blot, immunoprecipitation, and immunofluorescence. YCharOS consolidates its data into reports (one protein per report) available on Zenodo, a public repository controlled by CERN, to ensure open access. To enhance the visibility of their work, the group is progressively converting their Zenodo reports into F1000 articles, collected on the YCharOS Gateway, and indexed via PubMed. Their data is also accessible through searches on the Antibody Registry. The provided data is a valuable resource for researchers when selecting antibodies for specific applications, although certain limitations should be considered. The data accumulated thus far has illuminated the extent of the problem when poorly performing antibodies are employed in research. While the scientific community was already aware that this was likely a widespread issue, the establishment of a collaborative open science project with industry partners introduces an innovative solution that holds the potential to yield significant returns on investment in the public interest. This potential is substantiated by the number of antibodies that have either been withdrawn or had their recommended usage altered by the vendor. However, despite the discovery of high-performing renewable antibodies for most of the studied proteins, this accounts for a tiny fraction of the human proteome and the commercial antibody market. To realise the full potential of this work, end-users must adjust their antibody procurement and usage practises in line with the provided data. This editorial offers a guide on how individual scientists can utilise the YCharOS data, in addition to sharing the insights gained from the data thus far with the wider scientific community. |
format | Online Article Text |
id | pubmed-10579855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-105798552023-10-18 YCharOS open antibody characterisation data: Lessons learned and progress made Biddle, Michael S. Virk, Harvinder S. F1000Res Editorial YCharOS is a collaborative initiative aimed at characterising antibodies against the entire human proteome. As of August 2023, they have presented comprehensive knockout characterisation data for 812 antibodies and 78 proteins using techniques such as Western blot, immunoprecipitation, and immunofluorescence. YCharOS consolidates its data into reports (one protein per report) available on Zenodo, a public repository controlled by CERN, to ensure open access. To enhance the visibility of their work, the group is progressively converting their Zenodo reports into F1000 articles, collected on the YCharOS Gateway, and indexed via PubMed. Their data is also accessible through searches on the Antibody Registry. The provided data is a valuable resource for researchers when selecting antibodies for specific applications, although certain limitations should be considered. The data accumulated thus far has illuminated the extent of the problem when poorly performing antibodies are employed in research. While the scientific community was already aware that this was likely a widespread issue, the establishment of a collaborative open science project with industry partners introduces an innovative solution that holds the potential to yield significant returns on investment in the public interest. This potential is substantiated by the number of antibodies that have either been withdrawn or had their recommended usage altered by the vendor. However, despite the discovery of high-performing renewable antibodies for most of the studied proteins, this accounts for a tiny fraction of the human proteome and the commercial antibody market. To realise the full potential of this work, end-users must adjust their antibody procurement and usage practises in line with the provided data. This editorial offers a guide on how individual scientists can utilise the YCharOS data, in addition to sharing the insights gained from the data thus far with the wider scientific community. F1000 Research Limited 2023-10-16 /pmc/articles/PMC10579855/ /pubmed/37854875 http://dx.doi.org/10.12688/f1000research.141719.1 Text en Copyright: © 2023 Biddle MS and Virk HS https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial Biddle, Michael S. Virk, Harvinder S. YCharOS open antibody characterisation data: Lessons learned and progress made |
title | YCharOS open antibody characterisation data: Lessons learned and progress made |
title_full | YCharOS open antibody characterisation data: Lessons learned and progress made |
title_fullStr | YCharOS open antibody characterisation data: Lessons learned and progress made |
title_full_unstemmed | YCharOS open antibody characterisation data: Lessons learned and progress made |
title_short | YCharOS open antibody characterisation data: Lessons learned and progress made |
title_sort | ycharos open antibody characterisation data: lessons learned and progress made |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579855/ https://www.ncbi.nlm.nih.gov/pubmed/37854875 http://dx.doi.org/10.12688/f1000research.141719.1 |
work_keys_str_mv | AT biddlemichaels ycharosopenantibodycharacterisationdatalessonslearnedandprogressmade AT virkharvinders ycharosopenantibodycharacterisationdatalessonslearnedandprogressmade |